News and Trends 8 Feb 2019 Anti-CRISPR Proteins Could Improve Gene Editing Precision A research group in Denmark has found proteins in gut and soil microbes that can inhibit the action of CRISPR-Cas9 gene editing, a finding that could help to control the technology with more precision and less risk. Bacteria and viruses have fought an evolutionary arms race for millions of years. Bacteria evolved CRISPR systems to […] February 8, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 6 Feb 2019 British Biotech Spin-Offs Get €40M Funding to Treat Narcolepsy Orexia and Inexia, two new virtual companies spun out of Sosei Heptares, will develop drugs for neurological diseases such as narcolepsy with funding from Medicxi Ventures. The companies will develop drugs that activate two molecules called OX1 and OX2. These molecules act as receptors of orexin, a protein that regulates arousal, wakefulness and sleep. The […] February 6, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Feb 2019 Combo of Immunotherapy and Diabetes Drug Could Beat Breast Cancer A Finnish research group has combined two cancer drugs with the diabetes drug metformin, making mice with breast cancer survive for longer than when given the treatments individually. The combination therapy included metformin, which can inhibit tumor growth; the cancer drug venetoclax, which causes cancer cells to commit suicide; and a checkpoint inhibitor antibody, which […] February 6, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Feb 2019 Engineered Chicken Eggs: The Future of Cheap Drug Production? Scientists at the University of Edinburgh have produced high-quality human proteins in chicken eggs, a method that could be significantly cheaper than the current standard. The researchers engineered the DNA of chickens to make them produce human proteins in the egg white, from where they can be easily purified. In a study published on the […] February 6, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Feb 2019 Swedish Biotech Receives EU Grant for High-Accuracy Kidney Cancer Test The Swedish biotech Elypta has received a Horizon 2020 grant of €2.4M to fund a clinical trial of a blood and urine test that provides an accurate diagnosis of renal cell carcinoma. The clinical trial aims to validate Elypta’s technology as a monitoring tool in patients who have been treated for the kidney cancer renal […] February 4, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 1 Feb 2019 This Biotech Links the Gut Microbiome to Diseases Using Norwegian Poo In Norway’s capital city of Oslo, the biotech Bio-Me can rapidly screen for specific gut bacteria, gathering data from thousands of Norwegian stool samples to link the gut microbiome to diseases. Mission: To rapidly screen thousands of stool samples from a Norwegian population study and link the gut microbiome with disease. Client companies will then […] February 1, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 31 Jan 2019 Watch Strap Made of Recombinant Spider Silk Launches in Europe Sold by the luxury brand Omega, the watch strap is made with spider silk proteins that are brewed by genetically engineered bacteria. Spider silk is known in the textile industry for its strength, resilience, flexibility and light weight. However, it is not possible to ‘farm’ spiders to produce their silk at an industrial scale. The […] January 31, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2019 CRISPR Gene Editing Could Make Gluten Safe for Celiacs A Dutch research group is using the gene editing tool CRISPR-Cas9 to modify wheat gluten, letting people with celiac disease eat gluten without experiencing debilitating symptoms. In celiac disease, the immune system attacks gluten, causing damage to the intestine. This forces sufferers to stick to expensive gluten-free versions of foods such as bread, which […] January 31, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 31 Jan 2019 Novozymes Signs Deal to Develop Biodegradable Plastics The Danish enzyme manufacturer Novozymes has launched a joint development collaboration with the French biotech Carbios to commercialize biodegradable plastics. Under the agreement, Novozymes is to use its manufacturing muscle to scale up and produce Carbios’ plastic-degrading enzyme technology for Carbios’ subsidiary company Carbiolice. Carbiolice is to embed these enzymes into single-use plastics, such as […] January 31, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jan 2019 Danish Biotech’s Drug for Rare Metabolic Disease Aces Clinical Trial A drug, developed by the Danish biotech Orphazyme for a rare metabolic disease, has shown promising results in a phase II/III trial, reducing the disease’s progression by 74%. The 50 patients recruited into the trial suffered from Niemann-Pick disease type C, a metabolic disease in which proteins crucial for storing fat molecules such as cholesterol […] January 30, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Expert Advice 30 Jan 2019 Life Science Email Marketing Best Practices on a Limited Budget Email marketing is almost as old as the internet itself, and it’s just as relevant to modern businesses. To be in possession of someone’s email (especially when they want you to have it), means you have a direct line to their mind. Every economically active demographic uses email. Despite every kind of challenge […] January 30, 2019 - 8 minutesmins - By James Mathison Share WhatsApp Twitter Linkedin Email
More News! 29 Jan 2019 Antibiotic Nasal Gel for Surgical Infections Cruises Through Phase I An antibiotic nasal gel, developed by the UK company Destiny Pharma to treat drug-resistant bacterial infections, has shown no adverse effects in healthy volunteers in a phase I trial. Destiny’s antibiotic nasal gel is designed to prevent post-surgical infections of the bacterial species Staphylococcus aureus, which can come in the dangerous drug-resistant strain MRSA. “About […] January 29, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email